<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157153</url>
  </required_header>
  <id_info>
    <org_study_id>C1702</org_study_id>
    <nct_id>NCT04157153</nct_id>
  </id_info>
  <brief_title>First in Men Study: BIOMAG-I</brief_title>
  <official_title>BIOTRONIK - Safety and Clinical Performance of the - Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, first-in-man trial. Up to 115 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical follow-up visits will take place at 1, 6, and 12 months and annually thereafter
      until 36 months post procedure.

      All subjects will undergo an angiographic follow-up at 6- and 12-month follow up.

      IVUS, (including IVUS-VH documentation) and OCT will be performed for all subjects at 6-month
      and 12-month follow-up (if the safety of the subject allows it and as per the investigator's
      decision).

      Vasomotion will be assessed angiographically with Acetylcholine followed by Nitroglycerine at
      12 months follow up in a subgroup of subjects, upon the investigators discretion and if
      subject consents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In scaffold late lumen loss</measure>
    <time_frame>At 6 months after index procedure</time_frame>
    <description>Independent Core Lab Assessment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be implanted with the Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold System (DREAMS 3G) and followed up until 36 monts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold</intervention_name>
    <description>Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is &gt; 18 years and &lt; 80 years of age

          2. Written subject informed consent available prior to PCI

          3. Subject eligible for PCI

          4. Subjects with a maximum of two single lesions in two separate coronary arteries which
             have to be de novo lesions and can be covered with 1 device each

          5. Reference vessel diameter between 2.5-4.2 mm by visual estimation, depending on the
             scaffold size used

          6. Target lesion length ≤ 28 mm by visual estimation, depending on the scaffold size used

          7. Target lesion stenosis by visual estimation &gt; 50% - &lt; 100% and TIMI flow ≥1 (assisted
             by e.g. QCA / IVUS /FFR).

          8. Subjects with stable or unstable angina pectoris or documented silent ischemia or
             hemodynamically stable NSTEMI patients without angiographic evidence of thrombus at
             target lesion

          9. Eligible for Dual Anti Platelet Therapy (DAPT)

        Exclusion Criteria:

          1. Pregnant or breast-feeding females or females who intend to become pregnant during the
             time of the study

          2. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute ST elevation myocardial infarction (STEMI) within 72 hours prior to the index
             procedure.

          3. Left main coronary artery disease

          4. Three-vessels with coronary artery disease requiring treatment at time of procedure

          5. Planned interventional treatment of any non-target vessel within 12-month
             post-procedure

          6. Subjects on dialysis

          7. Planned intervention of the target vessel post index procedure

          8. Ostial target lesion (within 5.0 mm of vessel origin)

          9. Target lesion involves a side branch &gt;2.0 mm in diameter

         10. Documented left ventricular ejection fraction (LVEF) ≤ 30% within the last 6 months

         11. Heavily calcified lesion

         12. Target lesion is located in or supplied by an arterial or venous bypass graft

         13. Target lesion requiring treatment with a device other than the non-compliant
             pre-dilatation balloon or scoring balloon prior to scaffold placement (including but
             not limited to rotational atherectomy, etc.)

         14. Unsuccessful pre-dilatation, defined as a residual stenosis rate more than 20%,
             estimated by any method and/or angiographic complications (e.g. distal embolization,
             side branch closure, extensive dissections)

         15. Known allergies to: Acetylsalicylic Acid (ASA), P2Y12 inhibitors, Heparin, Contrast
             medium, Sirolimus, or similar drugs; or the scaffold material

         16. Subject is receiving an oral or intravenous immuno-suppressive therapy (e.g., inhaled
             steroids are not excluded) or has a known life-limiting immunosuppressive or
             autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus)
             diabetes mellitus is not excluded)

         17. A stenosis located proximal or distal to the target lesion that might require future
             revascularization or an impede run off detected during diagnostic angiography

         18. Life expectancy less than 1 year

         19. Planned surgery or dental surgical procedure within 6 months after index procedure
             unless DAPT will be maintained

         20. In the investigators opinion, subject will not be able to comply with the follow-up
             requirements

         21. Subject is currently participating in another study with an investigational device or
             an investigational drug and has not reached the primary endpoint yet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Haude, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheinland Klinikum Lukaskrankenhaus Neuss</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Sauter, PhD</last_name>
    <phone>+41448645575</phone>
    <phone_ext>5575</phone_ext>
    <email>stephanie.sauter@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Souheila Moutiq, Msc</last_name>
    <phone>+41448645575</phone>
    <phone_ext>5625</phone_ext>
    <email>souheila.moutiq@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabor Toth, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Verheye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ferdinande Bert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johann Bennett, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralph Toelg, PD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz-und Gefäßzentrum Oberallgäu-Kempten</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Torzewski, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcus Wiemer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum</name>
      <address>
        <city>Münich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Joner, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheinland Klinikum Lukaskrankenhaus Neuss</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Haude, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis Amsterdam (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rene van der Schaaf, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miedziowe Centrum Zdrowia SA</name>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrian Włodarczak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Göran Olivecrona, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva HUG</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Iglesias, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

